These results support the hypothesis that a dual A1/A2A AR antagonist may provide additional benefit to PD patients as compared to antagonists that selectively block A2A ARs, due to their positive effects on cognitive impairment often associated with the disease. This evidence concerns the gene AR and Parkinson disease.